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Objectives. We examined the possible association between the
missense Glu298Asp variant of the endothelial nitric oxide syn-
thase (eNOS) gene and myocardial infarction (MI).
Background. Endothelium-derived nitric oxide (NO) plays a
key role in the regulation of vascular tone. Recently, we reported
that a missense Glu298Asp variant in exon 7 of the eNOS gene is
a possible genetic factor involved in the pathogenesis of coronary
spasm. Endothelium-derived NO also has vasoprotective effects by
suppressing platelet aggregation, leukocyte adhesion and smooth
muscle cell proliferation.
Methods. We screened 285 patients with an MI and 607 control
subjects in Kumamoto Prefecture, Japan. Genotypes were deter-
mined by polymerase chain reaction–restriction fragment-length
polymorphism analysis.
Results. The frequency of the missense Glu298Asp variant was
significantly higher in the MI group than in the control group
(21.1% vs. 13.3%, p 5 0.003, odds ratio 1.73 for the dominant effect
of the eNOS T allele). Multiple logistic regression analysis showed
that the missense Glu298Asp variant was an independent risk
factor for MI, as was diabetes mellitus, hypertension, cigarette
smoking, hypercholesterolemia and body mass index.
Conclusions. There was a significant association of the mis-
sense Glu298Asp variant of the eNOS gene with MI. This marker–
disease association may be due to the impaired effects of NO on
the cardiovascular system: dysregulation of vascular tone, platelet
aggregation and leukocyte adhesion and smooth muscle cell
proliferation, all of which promote coronary atherosclerosis and
thrombosis.
(J Am Coll Cardiol 1998;31:1506–10)
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Epidemiologic studies (1–4) have shown that hyperlipidemia,
hypertension, cigarette smoking, diabetes mellitus, obesity and
family history of ischemic heart disease are the risk factors for
coronary heart disease. Although the accumulation of coro-
nary risk factors often leads to acute myocardial infarction
(AMI), its precise pathogenesis has not been elucidated. AMI
may arise from interactions between environmental and ge-
netic risk factors.
We recently identified a missense variant within exon 7 of
the endothelial nitric oxide synthase (eNOS) gene in patients
with coronary spastic angina—GAG to GAT substitution,
which results in the replacement of glutamic acid by aspartic
acid (Glu298Asp)—and found that this variant is significantly
associated with coronary spasm (5). Coronary spasm is a cause
of variant angina, or coronary spastic angina, and is also
involved in the pathogenesis of AMI (6–10). The variant may
be a possible genetic risk factor for AMI as well as coronary
spasm.
eNOS is present in the vascular endothelium (11–15),
platelets (16) and several other cell types that continuously
produce modest amounts of nitric oxide (NO). Endothelium-
derived NO plays a key role in the regulation of vascular tone
(17–19) and has vasoprotective effects by scavenging superox-
ide radicals and suppressing platelet aggregation, leukocyte
adhesion and smooth muscle cell proliferation (19–22). The
impaired effects of NO on the cardiovascular system appear to
be responsible for coronary atherosclerosis and thrombosis.
In the present study, we examined the possible association
between the missense Glu298Asp variant and myocardial
infarction (MI). We also investigated coronary risk factors,
including the insertion/deletion (I/D) polymorphism of the
angiotensin-converting enzyme (ACE) gene, which was re-
cently identified as a possible genetic risk factor for MI
(23–25).
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Methods
Study subjects. Patients. The study included 285 patients
with an AMI (219 men, 66 women; mean age 57 years, range 15
to 70 at onset of MI) admitted to Kumamoto University
Hospital and the university-affiliated hospitals in Kumamoto
Prefecture from October 1994 to February 1997. Diagnosis of
AMI was made by chest symptoms, electrocardiographic
changes and serum creatine kinase-MB isoenzyme (CK-MB)
elevations more than twice the upper level of normal. Cardiac
catheterization analyses, including coronary angiography and
left ventriculography, were performed in the acute phase.
Coronary artery stenosis was defined as significant when the
lumen diameter was .50% narrowed after nitroglycerin ad-
ministration. One hundred thirty-seven (48.1%), 71 (24.9%)
and 61 (21.4%) patients had single-, double- and triple-vessel
disease, respectively; the remaining 16 (5.6%) had no organic
stenosis.
Written informed consent was obtained from all patients
studied in the hospital. The study was in agreement with the
guidelines approved by the ethics committee of Kumamoto
University School of Medicine.
Control subjects. The study also included 607 age-matched
volunteers as control subjects (403 men, 204 women; mean age
56 years, range 24 to 78) living in Kumamoto Prefecture,
Japan. They underwent a check-up examination at the Japa-
nese Red Cross Kumamoto Health Care Center from April to
June 1996 that included determination of plasma lipid levels,
blood pressure, smoking habit, blood glucose levels after oral
glucose loading and body mass index and acquisition of chest
X-ray film and an exercise ECG. They had no chest symptoms,
and none had an MI.
Screening for the missense Glu298Asp variant of the eNOS
gene by polymerase chain reaction–restriction fragment-
length polymorphism. Genomic DNA was prepared from
blood leukocytes by established methods (26). The presence of
the missense Glu298Asp variant was determined by polymer-
ase chain reaction–restriction fragment-length polymorphism
(PCR-RFLP) analysis. A set of primers was designed to
amplify the 248-base pair (bp) fragment encompassing the
missense Glu298Asp variant (the sense and antisense primers
59-AAGGCAGGAGACAGTGGATGGA-39 and 59-
CCCAGTCAATCCCTTTGGTGCTCA-39, respectively). The
PCR fragments were digested with the restriction enzyme Ban
II, separated by electrophoresis using low melting temperature
agarose gel (4%, NuSieve GTG AGAROSE, FMC) and
visualized by ethidium bromide staining. The mutant allele (T)
has no Ban II cutting site (Fig. 1).
Screening for the ACE insertion/deletion polymorphism by
PCR amplification. Genotyping for the insertion/deletion
(I/D) polymorphism of the ACE gene was examined by PCR
amplification, as previously described (27–29). The reaction
included 5% dimethyl sulfoxide (DMSO) to ensure that the I
allele was amplified in all heterozygotes (28).
To avoid potential misclassification of the ID genotype,
which may appear as DD because of the preferential amplifi-
cation of the D allele in heterozygous samples, each sample
found to have the DD genotype was subjected to the second,
independent PCR amplification. The primer pair (59-
TGGGACCACAGCGCCCGCCACTAC-39 and 5 9 -
TCGCCAGCCCTCCCATGCCCATAA-39) recognizes an
insertion-specific sequence. The reaction yields a 335-bp frag-
ment only in the presence of I allele and no product in samples
homozygous for DD (29).
Evaluation of coronary risk factors. The coronary risk
factors of all subjects were assessed by history and chart review.
Hypertension was defined by history of several blood pressure
measurements elevated either systolically (.160 mm Hg) or
diastolically (.95 mm Hg). Diabetes mellitus was defined by
elevated blood glucose levels after fasting (.7.8 mmol/liter
[140 mg/dl]) or 2 h after 75 g of oral glucose loading (.11.1
mmol/liter [200 mg/dl]). Hypercholesterolemia was defined by
elevated total serum cholesterol levels (.6.21 mmol/liter [240
mg/dl]). Subjects were also classified as smokers (current and
ex-smokers) and nonsmokers.
Statistical analysis. Chi-square analysis and an unpaired t
test were used to compare the frequencies of the missense
Glu298Asp variant and other coronary risk factors, including
age, gender, body mass index, hypertension, diabetes mellitus,
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AMI 5 acute myocardial infarction
bp 5 base pairs
CK 5 creatine kinase
ECG 5 electrocardiogram, electrocardiographic
eNOS 5 endothelial nitric oxide synthase
I/D 5 insertion/deletion
MI 5 myocardial infarction
NO 5 nitric oxide
PCR-RFLP 5 polymerase chain reaction–restriction fragment-length
polymorphism
Figure 1. Use of PCR-RFLP analysis to screen for the missense
Glu298Asp mutation; G to T substitution at nucleotide position 894 of
the eNOS cDNA. Shown is a representative agarose gel loaded with
three PCR products of Glu298Asp homozygote (TT), Glu298Asp
heterozygote (TG) and wild-type (GG) after digestion with Ban II,
respectively.
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hypercholesterolemia and cigarette smoking, between the MI
and the control groups. The Hardy-Weinberg equilibrium was
tested by chi-square analysis for the frequencies of the eNOS
and ACE genotypes (29).
Odds ratios (approximating to relative risk) were calculated
as a measure of the association between the eNOS genotype
and the phenotype of MI, with the effects of the T (mutant)
allele assumed to be additive (T allele vs. G allele) or dominant
(TT and TG combined vs. GG). Odds ratios were also calcu-
lated for the ACE genotype, with the effects of the D allele
assumed to be additive (D allele vs. I allele), recessive (DD vs.
ID and II combined) or dominant (DD and ID combined vs.
II) (29). For each odds ratio, we calculated two-tailed p values
and 95% confidence intervals.
To determine the independent risk factors for MI, we
performed multiple logistic regression analysis for the effect of
the missense Glu298Asp variant, the ACE I/D polymorphism
and other coronary risk factors for MI. The analysis was
performed using SPSS Advanced Statistics 6.1 for Macintosh
(SPSS Japan Inc., Japan). All independent variables were
coded as dummy variables (age: 0 for ,60 years, 1 for $60
years; gender: 0 for female, 1 for male; body mass index: 0 for
,26 kg/m2, 1 for $26 kg/m2; hypertension, diabetes mellitus
and hypercholesterolemia: 0 for absence, 1 for presence;
cigarette smoking: 0 for nonsmoker, 1 for current or ex-
smoker; missense Glu298Asp variant: 0 for GG, 1 for TG and
TT combined [dominant effect of the T allele]; ACE I/D
polymorphism: 0 for II, 1 for ID and DD combined [dominant
effect of the D allele]). We used forward stepwise selection
(Wald criterion) in this analysis. Statistical significance was
defined as p , 0.05.
Results
Screening for the missense Glu298Asp variant of the eNOS
gene and univariate analysis. Figure 1 shows a representative
agarose gel loaded with three PCR products after digestion
with Ban II. The eNOS/TT, TG and GG genotypes were
present in 1 (0.4%), 59 (20.7%) and 225 (78.9%) of 285
patients with an MI, respectively. In contrast, the eNOS/TT,
TG and GG genotypes were found in 1 (0.2%), 80 (13.2%) and
526 (86.7%) of 607 control subjects, respectively. The genotype
frequencies were in agreement with those predicted by the
Hardy-Weinberg equilibrium. In the analyses of the additive
and dominant effects of the eNOS T allele, each frequency was
significantly higher in the MI group than in the control group
(p 5 0.035 and 0.003, respectively), as shown in Table 1.
The missense Glu298Asp variant was found in 2 (12.5%) of
16 patients with no organic stenosis, 33 (24.1%) of 137 patients
with single-vessel disease (vs. no organic stenosis, p 5 NS), 15
(21.1%) of 71 patients with double-vessel disease (vs. no
organic stenosis, p 5 NS) and 10 (16.4%) of 61 patients with
triple-vessel disease (vs. no organic stenosis, p 5 NS). We
found no significant association between the eNOS variant and
the number of diseased vessels in the MI group.
Screening for the ACE I/D polymorphism and univariate
analysis. Figure 2 shows representative agarose gels loaded
with the PCR products of the first and second amplifications
for the ACE gene. The second PCR results completely
matched with the first ones. The ACE/DD, ID and II geno-
types were present in 32 (11.2%), 137 (48.1%) and 116 (40.7%)
of 285 patients with an MI and in 71 (11.7%), 284 (46.8%) and
252 (41.5%) of 607 control subjects. The genotype frequencies
were in agreement with those predicted by the Hardy-
Weinberg equilibrium. In each analysis of the additive, reces-
sive and dominant effects of the ACE D allele, each frequency
was not different between the MI and control groups (p 5
0.919, 0.838 and 0.818, respectively).
Comparison of MI and control groups for coronary risk
factors. We compared the MI and control groups for frequen-
cies of coronary risk factors, including age, gender, hypercho-
lesterolemia, cigarette smoking, hypertension, diabetes melli-
tus and body mass index. There were significant differences in
Figure 2. Use of PCR amplification to screen for the ACE I/D
polymorphism. Shown are representative agarose gels loaded with
three DNA samples of DD, ID and II after the first (A) and second (B)
PCR amplification, respectively. The second PCR amplification was
performed to avoid misclassifying the ID genotype as DD, with use of
the insertion-specific primers. The primers create a product (335 base
pairs [bp]) only in the presence of the insertion.
Table 1. Frequency of Genotypes of Endothelial Nitric Oxide
Synthase Gene in Control Subjects and Patients With
Myocardial Infarction
Control Group
(n 5 607)
MI Group
(n 5 285)
OR
(95% CI) p Value
eNOS Glu298Asp var
eNOS/TT 1/607 (0.2%) 1/285 (0.4%) — —
eNOS/TG 80/607 (13.2%) 59/285 (20.7%) — —
eNOS/GG 526/607 (86.7%) 225/285 (78.9%) — —
T allele vs. G allele — — 1.6 (1.0–2.7) 0.035
TT and TG vs. GG — — 1.7 (1.2–2.4) 0.003
Data presented are number (%) of patients, unless otherwise indicated. CI 5
confidence interval; eNOS 5 endothelial nitric oxide synthase; eNOS/GG 5
homozygous normal; eNOS/TG 5 heterozygous carriers of the eNOS
Glu298Asp variant; eNOS/TT 5 homozygous carriers of the eNOS Glu298Asp
variant; MI 5 myocardial infarction; OR 5 odds ratio; var 5 variant.
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the frequencies of gender (p 5 0.002), body mass index
(p 5 0.002), hypertension (p , 0.001), diabetes mellitus
(p , 0.001), hypercholesterolemia (p , 0.001) and cigarette
smoking (p , 0.001) between the MI and control groups, as
shown in Table 2.
Multiple logistic regression analysis. Table 3 shows the
results of multiple logistic regression analysis with forward
stepwise selection (Wald) using all independent variables.
Exp(b) is represented by odds ratios in Table 3. The analysis
revealed that the independent risk factors for MI were diabetes
mellitus (p , 0.001), hypertension (p , 0.001), cigarette
smoking (p , 0.001), hypercholesterolemia (p , 0.001), body
mass index (p 5 0.022) and the missense Glu298Asp variant
(p 5 0.039).
Discussion
Present study. We found a significant difference in the
frequency of the missense Glu298Asp variant of the eNOS
gene between the MI and control groups: The missense
Glu298Asp variant (heterozygote [TG] and homozygote [TT]
combined) was present in 21.1% of patients with an MI but in
only 13.3% of control subjects. The frequency of the variant
was significantly higher in the MI group than in the control
group (p 5 0.003). Multiple logistic regression analysis to
determine the independent risk factors for MI revealed that
the missense Glu298Asp variant was one of the independent
risk factors for MI. Thus, the present study shows that the
missense Glu298Asp variant is significantly associated with MI.
In such an association study between genetic marker and
disease, population stratification should be controlled, and
genotyping methods should be appropriate. In our study, we
applied the following approach 1) We recruited 285 patients
with a definite diagnosis of MI by chest symptoms, ECG
changes and CK-MB elevations more than twice the upper
level of normal. 2) The control group included subjects with no
MI from the same general population as the patients and with
a similar age distribution (56 6 10 vs. 57 6 10 years). 3) The
distribution of the missense Glu298Asp variant and ACE I/D
polymorphism was matched to the Hardy-Weinberg equilib-
rium. This approach suggests that there were no apparent
genotyping errors and that the genetic background of the study
subjects was homogeneous.
Previous studies. Recently, some studies showed (23–25) a
significant association between the ACE D allele and MI in low
risk subgroups, whereas others found no such association
(29,31,32). In the present study, there was no significant
association between the ACE I/D polymorphism and MI in
both the total cohort and low risk subjects with low levels of
total serum cholesterol (,6.21 mmol/liter) and a low body
mass index (,26 kg/m2) (data not shown). In the patients and
control subjects of the present study, the distributions of the
ACE genotypes were in agreement with the Hardy-Weinberg
equilibrium, although other studies in Japanese (33) have
shown distributions that deviated from it.
The association between the missense Glu298Asp variant of
the eNOS gene and MI is not understood at present. It has
been shown that endothelium-derived NO plays a key role in
the regulation of vascular tone (17–19) and that it scavenges
superoxide radicals and suppresses platelet aggregation, leu-
kocyte adhesion and smooth muscle cell proliferation (19–22).
Dysregulated NO production by the mutant eNOS may pro-
mote coronary atherosclerosis and thrombosis.
Wang et al. (34) have recently reported that a smoking-
dependent risk of ischemic heart disease is associated with a
polymorphism ecNOS4a/b in intron 4 of the eNOS gene. In
this regard, the data of the present study have added another
example of an association between a polymorphism/mutation
of the eNOS gene and cardiovascular disorders.
Study limitations. We examined the distribution of the
missense Glu298Asp variant in 607 volunteer control subjects,
representative of the general population of Kumamoto Prefec-
ture, and found that the frequency of the variant was 13.3%.
However, it is possible that some volunteers were highly health
conscious and underwent a check-up examination because of a
family history of ischemic heart disease. Furthermore, we
cannot exclude that myocardial ischemia might have been
present in some control subjects. The frequency of the muta-
tion may be lower than 13.3% in the actual general population.
These volunteers with the mutation should be evaluated in
further, prospective studies.
Table 2. Clinical Characteristics of Study Subjects
Control Group
(n 5 607)
MI Group
(n 5 285) p Value
Age (yr) 56 6 10 57 6 10 0.121
Men/women 403/204 219/66 0.002
BMI (kg/m2) 23.3 6 2.9 24.0 6 3.3 0.002
HTN 101/607 (17%) 114/285 (40%) , 0.001
DM 51/607 (8%) 85/285 (30%) , 0.001
Hyperchol 121/607 (20%) 110/285 (39%) , 0.001
Cig smoker 283/607 (47%) 202/285 (71%) , 0.001
Data presented are mean value 6 SD or number (%) of patients. BMI 5
body mass index; Cig 5 cigarette; DM 5 diabetes mellitus; HTN 5 hyperten-
sion; Hyperchol 5 hypercholesterolemia; MI 5 myocardial infarction.
Table 3. Results of Multiple Logistic Regression Analysis: Final
Significant Variables in Equation Using Forward Stepwise
Selection (Wald)
Variable
Beta-
Coeff SE
p
Value*
OR†
(95% CI)
DM 1.331 0.215 , 0.001 3.7 (2.1–6.6)
HTN 1.213 0.184 , 0.001 3.3 (2.1–5.2)
Cig smoker 1.183 0.172 , 0.001 3.2 (2.1–4.8)
Hyperchol 0.783 0.178 , 0.001 2.1 (1.6–2.8)
BMI 0.455 0.199 0.022 1.5 (1.3–1.8)
Glu298Asp var‡ 0.437 0.212 0.039 1.5 (1.2–1.8)
Constant 22.397 0.177 , 0.001 —
*One degree of freedom. †Exp(beta). ‡eNOS/TT (homozygous carriers of
eNOS Glu298Asp variant) and eNOS/TG (heterozygous carriers of the eNOS
Glu298Asp variant) combined. Coeff 5 coefficient; other abbreviations as in
Tables 1 and 2.
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The functional significance of the missense Glu298Asp
variant of the eNOS gene has not yet been demonstrated. Our
computer analysis revealed that glutamic acid at position 298 is
in an alpha-helix and that the missense Glu298Asp variant
results in a tight turn (35) (unpublished data), suggesting that
the missense Glu298Asp variant may affect the function of
eNOS protein. However, X-ray diffraction by protein crystals is
required to determine the exact three-dimensional structure
and gain an understanding of the molecular basis of the
protein’s function.
Conclusions. The present study found a significant associ-
ation between the missense Glu298Asp variant of the eNOS
gene and MI. Thus, we suggest that the presence of the
missense Glu298Asp variant of the eNOS gene is a possible
genetic risk factor for MI.
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